FINCH THERAPEUTICS GROUP, INC. Research and Development Expense
FINCH THERAPEUTICS GROUP, INC. reported Research and Development Expense of $0 for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-08-13
- FINCH THERAPEUTICS GROUP, INC. research and development expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for fiscal 2023 was $7.20M, a 86.38% decline from fiscal 2022.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for fiscal 2022 was $52.86M, a 7.71% decline from fiscal 2021.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for fiscal 2021 was $57.28M, a 72.82% increase from fiscal 2020.
- FINCH THERAPEUTICS GROUP, INC. research and development expense for fiscal 2020 was $33.14M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-05-10 | $0.00 derived: sum of 3 quarters · filed 2024-05-10 | $203.00K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $203.00K derived: sum of 3 quarters · filed 2024-08-13 | $7.20M 10-K · filed 2024-03-25 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $203.00K derived: sum of 2 quarters · filed 2024-08-13 | $7.20M 10-Q · filed 2023-11-08 | $18.75M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-06-30 | $203.00K 10-Q · filed 2024-08-13 | $7.20M 10-Q · filed 2024-08-13 | $18.75M derived: sum of 3 quarters · filed 2024-08-13 | $30.61M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $7.00M 10-Q · filed 2024-05-10 | $8.59M 10-Q · filed 2023-05-10 | $18.55M derived: sum of 2 quarters · filed 2024-05-10 | $30.41M derived: sum of 3 quarters · filed 2024-05-10 | $44.33M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $23.41M derived: sum of 2 quarters · filed 2024-03-25 | $37.33M derived: sum of 3 quarters · filed 2024-03-25 | $52.86M 10-K · filed 2024-03-25 | $57.89M 10-K · filed 2023-03-23 | |
| 2022-09-30 | $11.86M 10-Q · filed 2023-11-08 | $25.78M derived: sum of 2 quarters · filed 2023-11-08 | $41.31M 10-Q · filed 2023-11-08 | $56.12M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $13.92M 10-Q/A · filed 2023-08-11 | $29.45M 10-Q/A · filed 2023-08-11 | $44.26M derived: sum of 3 quarters · filed 2023-08-11 | $59.79M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $15.53M 10-Q · filed 2023-05-10 | $30.33M derived: sum of 2 quarters · filed 2023-05-10 | $45.87M derived: sum of 3 quarters · filed 2023-05-10 | $59.83M derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $30.34M derived: sum of 2 quarters · filed 2023-03-23 | $44.30M derived: sum of 3 quarters · filed 2023-03-23 | $57.28M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | $15.54M 10-Q · filed 2022-11-10 | $29.50M derived: sum of 2 quarters · filed 2022-11-10 | $42.48M 10-Q · filed 2022-11-10 | $51.04M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $13.96M 10-Q · filed 2022-08-11 | $26.94M 10-Q · filed 2022-08-11 | $35.51M derived: sum of 3 quarters · filed 2022-08-11 | $44.55M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $12.97M 10-Q · filed 2022-05-16 | $21.54M derived: sum of 2 quarters · filed 2022-05-16 | $30.59M derived: sum of 3 quarters · filed 2022-05-16 | $38.72M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $17.61M derived: sum of 2 quarters · filed 2022-03-31 | $25.75M derived: sum of 3 quarters · filed 2022-03-31 | $33.14M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $9.04M 10-Q · filed 2021-11-10 | $17.18M derived: sum of 2 quarters · filed 2021-11-10 | $24.58M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $8.13M 10-Q · filed 2021-08-10 | $15.53M 10-Q · filed 2021-08-10 | ||||
| 2020-03-31 | $7.40M 10-Q · filed 2021-05-13 |